Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Purchased by Toronto Dominion Bank

Toronto Dominion Bank raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,747 shares of the medical equipment provider's stock after purchasing an additional 8,710 shares during the quarter. Toronto Dominion Bank's holdings in Zimmer Biomet were worth $7,421,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Neo Ivy Capital Management acquired a new position in Zimmer Biomet in the 3rd quarter worth approximately $150,000. Brown Financial Advisors increased its stake in shares of Zimmer Biomet by 16.6% in the third quarter. Brown Financial Advisors now owns 9,566 shares of the medical equipment provider's stock worth $1,033,000 after acquiring an additional 1,361 shares during the period. Geode Capital Management LLC lifted its position in Zimmer Biomet by 2.6% during the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider's stock valued at $524,942,000 after purchasing an additional 125,852 shares during the period. M&T Bank Corp boosted its holdings in Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider's stock valued at $2,884,000 after purchasing an additional 8,709 shares during the last quarter. Finally, LRI Investments LLC grew its position in Zimmer Biomet by 112.4% during the 3rd quarter. LRI Investments LLC now owns 1,094 shares of the medical equipment provider's stock worth $119,000 after purchasing an additional 579 shares during the period. Hedge funds and other institutional investors own 88.89% of the company's stock.

Analyst Ratings Changes

A number of brokerages have recently commented on ZBH. BTIG Research lowered their target price on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating on the stock in a research note on Thursday, October 3rd. Barclays dropped their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an "underweight" rating on the stock in a research note on Thursday. Oppenheimer decreased their target price on shares of Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research note on Tuesday, October 15th. Needham & Company LLC restated a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Wolfe Research began coverage on shares of Zimmer Biomet in a report on Tuesday, September 10th. They issued a "peer perform" rating for the company. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and a consensus target price of $122.83.

Zimmer Biomet Price Performance

Shares of NYSE:ZBH traded down $0.10 during midday trading on Friday, hitting $106.74. The company's stock had a trading volume of 1,195,338 shares, compared to its average volume of 1,361,031. Zimmer Biomet Holdings, Inc. has a 12-month low of $101.47 and a 12-month high of $133.90. The company has a market cap of $21.25 billion, a P/E ratio of 20.29, a price-to-earnings-growth ratio of 1.96 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36. The business's 50 day simple moving average is $107.69 and its 200 day simple moving average is $108.65.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business had revenue of $1.82 billion for the quarter, compared to analysts' expectations of $1.80 billion. During the same period in the previous year, the firm posted $1.65 EPS. The business's revenue for the quarter was up 4.1% compared to the same quarter last year. On average, analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.